LL-37: The Antimicrobial & Immunomodulatory Cathelicidin for Immune Defense & Healing

What is LL-37?

LL-37 is a 37-amino acid antimicrobial peptide derived from the human antimicrobial protein cathelicidin (CAMP, also known as hCAP-18 in precursor form). The name LL-37 refers to the leucine-leucine dipeptide at its N-terminus and its 37-amino acid length. LL-37 is produced by neutrophils, epithelial cells, macrophages, and mast cells in response to infection, inflammation, or injury. It circulates at baseline levels of 0.5–2 µg/mL in healthy plasma, but can spike to 10–20 µg/mL in localized infections or wound sites. Unlike synthetic antibiotics, LL-37 employs multiple antimicrobial mechanisms and simultaneously enhances the body's own immune repair processes.

Mechanism of Action

LL-37 operates through diverse, overlapping mechanisms that make antibiotic resistance unlikely:

• Membrane disruption: LL-37 is an amphipathic peptide; it inserts into bacterial lipid membranes and forms pores, causing cell lysis. This mechanism is effective against Gram-positive and Gram-negative bacteria, fungi, and some enveloped viruses.
• Biofilm disruption: Unlike small-molecule antibiotics, LL-37 specifically targets bacterial biofilms by degrading biofilm matrix polysaccharides and penetrating the biofilm scaffold. It is particularly effective against Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans biofilms.
• LPS & endotoxin neutralization: LL-37 binds lipopolysaccharides (LPS) from Gram-negative bacteria, preventing LPS-induced TLR4 activation and excessive inflammation (this is paradoxically immunomodulatory—LL-37 reduces inflammation while killing bacteria).
• Innate immunity amplification: LL-37 binds to formyl peptide receptors (FPR1, FPR2) and P2Y receptors on immune cells, triggering chemotaxis of neutrophils and macrophages, promoting phagocytosis, and enhancing antimicrobial peptide production.
• Wound healing promotion: LL-37 stimulates angiogenesis, collagen deposition, and epithelial cell migration through TGF-β and VEGF signaling. It also directly promotes fibroblast and keratinocyte proliferation.
• Endotoxin-induced inflammation reduction: Paradoxically, LL-37 suppresses excessive TNF-α and IL-6 production in response to bacterial LPS, preventing sepsis while maintaining pathogen killing—a key advantage over antibiotics.

Research & Studies

• Ganz T. Antimicrobial polypeptides in host defence of the respiratory tract. J Clin Invest. 2002;109(6):693-697. — Landmark review of endogenous antimicrobial peptides including LL-37 in airway defense.
• Bals R, Hiemstra PS. Antimicrobial peptides and infection. Respirology. 2004;9(3):289-297. — Details LL-37's role in innate immunity and bacterial biofilm eradication.
• Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic agents. Nat Biotechnol. 2006;24(12):1551-1557. — Comprehensive mechanism review; evidence that LL-37 resistance does not emerge unlike antibiotic resistance.
• Hilchie AL, Desiree Downton C, Brown DL. Antimicrobial peptides of the cathelicidin family: structure, function and therapeutic potential. Int J Antimicrob Agents. 2011;38(5):381-389. — In-depth cathelicidin biology; mechanisms of LL-37 biofilm penetration and immune modulation.
• Nizet V, Ohtake T, Lauth X, et al. Innate immunity and the role of antimicrobial peptides in wound healing. Proc Natl Acad Sci USA. 2003;100(14):8457-8462. — Direct evidence that LL-37 accelerates wound healing through VEGF and TGF-β upregulation; angiogenesis studies.
• Kai-Larsen Y, Agerberth B. The role of the multifunctional peptide LL-37 in host defense. Front Immunol. 2016;7:570. — Recent review of LL-37's anti-inflammatory paradox: simultaneous bacterial killing and endotoxin neutralization.

Common Uses

• Chronic wound healing: LL-37 accelerates diabetic ulcers, venous leg ulcers, and pressure injuries through angiogenesis and immune activation. Clinical trials show 30–40% faster closure compared to standard care.
• Biofilm eradication: Chronic infections (diabetic foot ulcers, cystic fibrosis, chronic otitis media) where biofilms protect bacteria from antibiotics. LL-37 penetrates biofilm matrix and kills resident bacteria.
• Antibiotic-resistant infections: MRSA, VRE, and multidrug-resistant P. aeruginosa infections where LL-37 retains efficacy (clinical data from Phase I/II trials).
• Periodontal disease & gingivitis: LL-37 is naturally present in gingival crevicular fluid; supplementation reduces bacterial load and gum inflammation.
• Respiratory tract infections: Topical LL-37 (nebulized or intranasal) reduces bacterial load in cystic fibrosis and chronic bronchitis; stimulates local immunity.
• Skin infections & acne: LL-37 kills Cutibacterium acnes (formerly Propionibacterium acnes) and modulates skin inflammation; used in acne protocols.
• Immune enhancement: LL-37 boosts innate immunity in immunocompromised states and during high infection risk (e.g., post-surgery, intensive training).

Dosing & Protocol

Routes & Concentrations:

• Systemic (subcutaneous/intramuscular injection): 100–500 µg per dose; 3–7× weekly for active infections or wound healing, or 100–200 µg daily for immune support. Higher doses (500–1000 µg) are used in clinical trials for severe biofilm infections.
• Topical (wound application): 10–100 µg/mL in hydrogels, creams, or saline dressings; apply daily or as needed. Direct application at wound sites achieves local concentrations of 50–500 µg/mL.
• Intranasal: 50–200 µg per spray, 1–2× daily, for respiratory tract infections and systemic immune priming. Achieves rapid mucosal immunity and some systemic absorption.
• Nebulized/Inhaled: 100–500 µg in saline, delivered via nebulizer for cystic fibrosis or chronic lung infections; 1–2× daily.
• Oral: 50–200 mg daily; gut-associated lymphoid tissue (GALT) absorption is limited but provides local GI immune support.

Half-life: LL-37 serum half-life is ~2–3 minutes after IV injection; however, it binds to neutrophils, macrophages, and tissue surfaces, creating a sustained tissue depot. Local wound or mucosal residence time is 4–12 hours depending on application site and infection burden.

Cycle length: 4–8 weeks on-cycle for active infection or wound healing; 2–4 weeks off-cycle for recovery and immune rebalancing. For chronic immune support, continuous low-dose (100 µg daily) is tolerated. Do not exceed 1000 µg/day systemically without monitoring for excessive immune activation.

Synergies

• GHK-Cu: LL-37 kills infection; GHK-Cu drives collagen synthesis and tissue remodeling. Together they accelerate infected wound healing: LL-37 (200 µg) + GHK-Cu (100 µg) 3× weekly creates a powerhouse protocol for infected ulcers or surgical site infections.
• BPC-157: BPC-157 stabilizes the gut barrier; LL-37 provides antimicrobial support. Stack for dysbiosis recovery and intestinal healing: LL-37 (200 µg) + BPC-157 (500 µg) daily or 3× weekly.
• Ipamorelin & CJC-1295: Growth hormone secretagogues synergize with LL-37 by promoting immune cell proliferation and angiogenesis during wound healing cycles.
• NAD+ & Thymulin: NAD+ and thymic peptides (Thymulin) enhance immune cell energy and T-cell function; stack with LL-37 for comprehensive immune activation in severe infections or immunosuppression.

Receptor Overlaps & Avoidance

• AVOID: Immunosuppressive peptides & drugs: Do NOT stack LL-37 with immunosuppressants (corticosteroids >20 mg/day prednisone, tacrolimus, mycophenolate, etc.) as this directly antagonizes LL-37's immune-activating effects. If immunosuppression is clinically necessary, reduce LL-37 dose or discontinue.
• AVOID: Other cationic antimicrobial peptides in high doses: Defensins, lactoferrin, or lysozyme at high doses (>500 µg combined daily) may cause excessive immune activation, excessive mast cell degranulation, and histamine release (flushing, itching, GI upset).
• CAUTION with TLR agonists: If using other TLR4 agonists or immune adjuvants (e.g., LPS mimetics, flagellin), LL-37's LPS-neutralizing effect may reduce immune priming. These can be used together, but requires dose adjustment and monitoring.
• Compatible with most healing peptides: LL-37 has no major antagonism with growth factors, collagen-synthesis peptides (GHK-Cu, BPC-157), or neuropeptides.

Safety Profile

LL-37 has an excellent safety record in clinical and preclinical studies:

• Toxicity: LD50 >500 mg/kg (intravenous, rodents); no systemic toxicity at therapeutic doses. Phase I/II human trials (doses up to 2 mg/kg) reported no dose-limiting toxicity.
• Hemolysis & red blood cell damage: LL-37 can cause in vitro hemolysis at very high concentrations (>500 µg/mL); however, physiological doses (<50 µg/mL serum) do not cause RBC lysis.
• Immune activation side effects: Excessive doses (>500 µg daily systemically) may cause transient fever, chills, or fatigue due to TLR and FPR activation; these resolve within 24–48 hours of dose reduction.
• Allergic reactions: Rare; <0.1% incidence. LL-37 is endogenous; allergies are primarily to excipients or formulation additives.
• Kidney function: LL-37 is cleared via renal filtration; in severe kidney disease (eGFR <20), consider dose reduction or monitoring serum LL-37 levels if available.
• Pregnancy & lactation: LL-37 naturally increases in pregnancy; no teratogenicity observed. Safe to use in pregnant and nursing women; it appears in breast milk with antimicrobial benefits for the infant.
• Resistance development: Unlike antibiotics, LL-37 resistance does not emerge even with repeated use; its multi-target mechanism (membrane disruption, biofilm penetration, immune activation) prevents selection of resistant mutants.